ストックスクリーナーアプリを入手
2.24
1.75%
-0.04
アフターアワーズ：
2.23
-0.01
-0.45%
前日終値:
$2.28
開ける：
$2.24
24時間の取引高:
15,649
Relative Volume:
0.02
時価総額：
$15.72M
収益：
$2.43M
当期純損益:
$-11.03M
株価収益率:
0.0352
EPS:
63.6476
ネットキャッシュフロー:
$-3.75M
1週間 パフォーマンス:
+5.16%
1か月 パフォーマンス:
-0.44%
6か月 パフォーマンス:
-57.97%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$2.22
$2.32
1週間の範囲:
$2.07
$2.43
52週間の値動き範囲:
$1.75
$12.87
Vyome Holdings Inc Stock (HIND) Company Profile
Compare HIND vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HIND
Vyome Holdings Inc
|
2.24 | 16.00M | 2.43M | -11.03M | -3.75M | 63.65 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vyome Holdings Inc (HIND) 最新ニュース
Vyome Holdings (STU:24O0) PB Ratio : 0.00 (As of Apr. 11, 2026) - GuruFocus
Vyome Holdings, Inc. (HIND) stock price, news, quote and history - Yahoo Finance UK
Breaking News about Vyome Holdings, Inc.Common Stock (Nasdaq:HIND) - FinancialContent
Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026 - BioSpace
Vyome to present VT-1953 Phase 2 data at cancer research meeting By Investing.com - Investing.com South Africa
Vyome to present VT-1953 Phase 2 data at cancer research meeting - Investing.com
HIND Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
HIND Stock Price, Quote & Chart | VYOME HOLDINGS INC (NASDAQ:HIND) - ChartMill
Vyome Holdings bolsters financial position to support VT-1953 pivotal study through 2027 - Indian Pharma Post
RSLS Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Vyome Holdings Inc (HIND) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... By GuruFocus - Investing.com Canada
HIND Technical Analysis & Stock Price Forecast - Intellectia AI
HIND Should I Buy - Intellectia AI
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase - Business Wire
Vyome Holdings, Inc.: Fundamental Analysis and Financial Ratings | H1O | US92943X1046 - marketscreener.com
Vyome Holdings Reports Positive Phase 2 Clinical Results for VT-1953 Topical Gel in Malignant Fungating Wounds and Acne Treatment – 2026 Company Overview and Pipeline Update - Minichart
Vyome Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Vyome 10-K: $0.32M Revenue, $(4.86) Loss per Share - TradingView
Vyome (HIND) versus Its Competitors Critical Analysis - Defense World
Head-To-Head Comparison: Vyome (HIND) versus The Competition - Defense World
Vyome (HIND) vs. Its Rivals Head to Head Contrast - Defense World
Vyome (HIND) & The Competition Head to Head Analysis - Defense World
Reviewing Vyome (HIND) and Its Rivals - Defense World
HIND Stock Rallies 70% Pre-Market Today – Find Out Why - Stocktwits
RSLS SEC FilingsReShape Lifesciences Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Vyome (HIND) versus Its Rivals Financial Analysis - Defense World
Analyzing Vyome (HIND) & Its Peers - Defense World
Vyome (HIND) & Its Peers Financial Survey - Defense World
Critical Comparison: Vyome (HIND) versus The Competition - Defense World
Financial Contrast: Vyome (HIND) & The Competition - Defense World
Vyome’s Livechain Acquires Humanyze to Expand AI HR Analytics - TipRanks
Vyome Holdings Unit LiveChain to Acquire $5.8M Humanyze Notes, Issuing 25% Equity to Remus - TradingView
Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company - 01net
Livechain completes acquisition of senior, secured debt of Humanyze - marketscreener.com
Reviewing Vyome (HIND) and The Competition - Defense World
Head to Head Review: Vyome (HIND) and Its Rivals - Defense World
Comparing Vyome (NASDAQ:HIND) and Nanovibronix (NASDAQ:FEED) - Defense World
Vyome Therapeutics2026 Latest Shareholding - Tracxn
Reviewing Vyome (HIND) & The Competition - Defense World
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity - Bluefield Daily Telegraph
Critical Survey: Vyome (HIND) & Its Competitors - Defense World
Vyome (HIND) versus Its Competitors Financial Analysis - Defense World
Analyzing Vyome (HIND) & Its Competitors - Defense World
HIND Financials: Income Statement, Balance Sheet & Cash Flow | Vyome Holdings, Inc. - Stock Titan
Vyome Reports Positive Phase 2 Data for VT-1953 Gel - TipRanks
Vyome Holdings, Inc. Reports Positive Phase 2 Results for VT-1953 - TradingView
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months - The Joplin Globe
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Vyome raises $5.29 million to fund phase 3 trial of MFW treatment - Investing.com Nigeria
Vyome Holdings Inc (HIND) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):